
Precision Biosciences (DTIL) Stock Forecast & Price Target
Precision Biosciences (DTIL) Analyst Ratings
Bulls say
Precision BioSciences is poised for success as the only company targeting the direct elimination of cccDNA in the competitive landscape of HBV cure therapies, evidenced by the highly differentiated results of their PBGENE-HBV program, including the critical dismantling of the viral replication source. The company's other programs, such as PBGENE-DMD, have shown promising early data and a clear focus on functional restoration rather than mere dystrophin detection, supported by significant preclinical evidence and strong safety profile, positioning the company for future success and potentially transformative advancements in the treatment of DMD. Risks to the company's strong potential lie predominantly in the success of the clinical development and potential commercial launch expenses for their programs, as well as general risks associated with the biopharmaceutical industry.
Bears say
Precision BioSciences is a clinical-stage gene editing company with two highly differentiated gene editing programs currently in development for hepatitis B virus (HBV) and Duchenne muscular dystrophy (DMD). These programs show promise in addressing large patient populations with high unmet needs, but the limited near-term dataset size poses a high-risk/high-reward situation for investors. The company's upcoming key catalyst is the potential nucleos(t)ide-analog (NUC) withdrawal, which will depend heavily on physician alignment and could make or break the programs' success.
This aggregate rating is based on analysts' research of Precision Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Precision Biosciences (DTIL) Analyst Forecast & Price Prediction
Start investing in Precision Biosciences (DTIL)
Order type
Buy in
Order amount
Est. shares
0 shares